These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 33215270)

  • 21. Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors.
    Brell JM; Krishnamurthi SS; Rath L; Bokar JA; Savvides P; Gibbons J; Cooney MM; Meropol NJ; Ivy P; Dowlati A
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):547-53. PubMed ID: 22868341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
    Van Cutsem E; Verslype C; Beale P; Clarke S; Bugat R; Rakhit A; Fettner SH; Brennscheidt U; Feyereislova A; Delord JP
    Ann Oncol; 2008 Feb; 19(2):332-9. PubMed ID: 17986625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.
    Sen S; Kato S; Agarwal R; Piha-Paul S; Hess K; Karp D; Janku F; Fu S; Naing A; Pant S; Falchook G; Tang C; Wu X; Ye Y; Tsimberidou A; Subbiah V; Kurzrock R; Byers L; Westin S; Lim J; Bean S; Bass A; Nguyen L; Meric-Bernstam F; Hong D
    Br J Cancer; 2018 May; 118(11):1419-1424. PubMed ID: 29695765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.
    Patnaik A; Gadgeel S; Papadopoulos KP; Rasco DW; Haas NB; Der-Torossian H; Faltaos D; Potvin D; Tassell V; Tawashi M; Chao R; O'Dwyer PJ
    Target Oncol; 2022 Mar; 17(2):125-138. PubMed ID: 35347559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
    Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
    Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
    Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
    Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
    Kanda S; Goto K; Shiraishi H; Kubo E; Tanaka A; Utsumi H; Sunami K; Kitazono S; Mizugaki H; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Hozumi H; Tamura T
    Ann Oncol; 2016 Dec; 27(12):2242-2250. PubMed ID: 27765756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer.
    Gómez-Martín C; Salazar R; Montagut C; Gil-Martín M; Núñez JA; Puig M; Lin X; Khosravan R; Tursi JM; Lechuga MJ; Bellmunt J
    Invest New Drugs; 2013 Apr; 31(2):390-8. PubMed ID: 22615059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
    Aspeslagh S; Stein M; Bahleda R; Hollebecque A; Salles G; Gyan E; Fudio S; Extremera S; Alfaro V; Soto-Matos A; Soria JC
    Anticancer Drugs; 2017 Mar; 28(3):341-349. PubMed ID: 27977433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
    Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
    Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.
    McKeage MJ; Jameson MB; Ramanathan RK; Rajendran J; Gu Y; Wilson WR; Melink TJ; Tchekmedyian NS
    BMC Cancer; 2012 Oct; 12():496. PubMed ID: 23098625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.
    Hiret S; Isambert N; Gomez-Roca C; Bennouna J; Sassi M; de Mont-Serrat H; Fan J; Schnell D; Delord JP
    Invest New Drugs; 2018 Dec; 36(6):1044-1059. PubMed ID: 29808308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
    Kotasek D; Tebbutt N; Desai J; Welch S; Siu LL; McCoy S; Sun YN; Johnson J; Adewoye AH; Price T
    BMC Cancer; 2011 Jul; 11():313. PubMed ID: 21791058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
    Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
    J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
    Gatzemeier U; Pluzanska A; Szczesna A; Kaukel E; Roubec J; De Rosa F; Milanowski J; Karnicka-Mlodkowski H; Pesek M; Serwatowski P; Ramlau R; Janaskova T; Vansteenkiste J; Strausz J; Manikhas GM; Von Pawel J
    J Clin Oncol; 2007 Apr; 25(12):1545-52. PubMed ID: 17442998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.
    Hubbard J; Erlichman C; Toft DO; Qin R; Stensgard BA; Felten S; Ten Eyck C; Batzel G; Ivy SP; Haluska P
    Invest New Drugs; 2011 Jun; 29(3):473-80. PubMed ID: 20082116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial.
    Dittrich C; Königsberg R; Mittlböck M; Geissler K; Sahmanovic-Hrgovcic A; Pleiner-Duxneuner J; Czejka M; Buchner P
    Invest New Drugs; 2019 Feb; 37(1):127-138. PubMed ID: 29998365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
    Lam ET; Au JL; Otterson GA; Guillaume Wientjes M; Chen L; Shen T; Wei Y; Li X; Bekaii-Saab T; Murgo AJ; Jensen RR; Grever M; Villalona-Calero MA
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1019-29. PubMed ID: 20107799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial.
    Roth AD; Maibach R; Fazio N; Sessa C; Stupp R; Morant R; Herrmann R; Borner MM; Goldhirsch A; de Braud F
    Ann Oncol; 2004 May; 15(5):759-64. PubMed ID: 15111343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
    Dragovich T; Huberman M; Von Hoff DD; Rowinsky EK; Nadler P; Wood D; Hamilton M; Hage G; Wolf J; Patnaik A
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):295-303. PubMed ID: 17149608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.